![Ioannis MAMOUNAKIS | Research Associate | Doctor of Philosophy Computer Engineer and Informatics | The Centre for Research and Technology, Hellas, Thessaloníki | Chemical Process and Energy Resources Institute (CPERI) Ioannis MAMOUNAKIS | Research Associate | Doctor of Philosophy Computer Engineer and Informatics | The Centre for Research and Technology, Hellas, Thessaloníki | Chemical Process and Energy Resources Institute (CPERI)](https://i1.rgstatic.net/ii/profile.image/820006984105985-1572516308606_Q512/Ioannis-Mamounakis-2.jpg)
Ioannis MAMOUNAKIS | Research Associate | Doctor of Philosophy Computer Engineer and Informatics | The Centre for Research and Technology, Hellas, Thessaloníki | Chemical Process and Energy Resources Institute (CPERI)
![Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ : indications and utilisation in the UK. Interim findings from the Sloane Project | British Journal of Cancer Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ : indications and utilisation in the UK. Interim findings from the Sloane Project | British Journal of Cancer](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fsj.bjc.6603945/MediaObjects/41416_2007_Article_BF6603945_Fig1_HTML.gif)
Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ : indications and utilisation in the UK. Interim findings from the Sloane Project | British Journal of Cancer
ΜΑΜΟΥΝΑΣ ΙΩΑΝΝΗΣ | Διδάκτωρ Της Ψυχιατρικής Του Πανεπιστημίου Αθηνών - Άγχος - Αγχώδεις Διαταραχές – Κατάθλιψη - Αϋπνία & Άλλες Διαταραχές Ύπνου - Γνωσιακή Ψυχοθεραπεία - Θεραπεία Οικογένειας – Ζεύγους-Ψυχαναγκασμοί - Βουλιμία - Ανορεξία, Ψυχίατροι ...
![6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.,The Lancet - X-MOL 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.,The Lancet - X-MOL](https://xpic.x-mol.com/20190629%2F10.1016_S0140-6736%2819%2930650-6.jpg)